St. Jude today announced the first U.S. implant in the company’s LEADLESS II pivotal trial designed to evaluate the Nanostim™ leadless pacemaker for FDA approval. The world’s first retrievable, non-surgical pacemaker was implanted at The Mount Sinai Hospital in New York City by Dr. Vivek Reddy. The LEADLESS II pivotal trial is a prospective, non-randomized,
St. Jude Medical today announced the completion of its acquisition of Nanostim, Inc., a privately-owned developer of miniaturized, leadless pacemakers. The acquisition adds the world’s first and only leadless pacemaker to the St. Jude Medical product portfolio. According to the press release: Unlike conventional pacemakers that require a more invasive surgery, the Nanostim™ leadless pacemaker
Medtronic announced at TEDMED 2010 that it is working on leadless pacemakers. Dr. Stephen Osterle, senior vice president of medicine and technology and member of Medtronic’s Executive Management Team, unveiled the device. Osterle said that physicians will be able to control the device with a smart phone.
Nanostim is an early-stage AIMD company in Milpitas, CA that is developing a pacemaker that can be implanted inside the heart through a catheter. The tiny device is attached directly to the heart, eliminating the need for leads. In May 2011 Nanostim announced that St. Jude Medical had made a substantial investment in the company. The company is operating in
Image Credit: University of Rochester Nuclear energy cells that converted the impact of the β-particles on a p-n junction were developed in the 1970s. One example was CCC’s atomic pacemaker, which was powered by a promethium-147 McDonell-Douglas Betacel 400. Lately, BetaBatt Inc. of Houston, TX licensed beta-voltaic technology developed at the University of Rochester to develop an